These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 19912214)

  • 1. Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN management protocol [corrected].
    de Sica-Chapman A; Williams G; Soni N; Bunker CB
    Br J Dermatol; 2010 Apr; 162(4):860-5. PubMed ID: 19912214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Ang CC; Tay YK
    Int J Dermatol; 2011 Dec; 50(12):1570-8. PubMed ID: 22098009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis.
    Goulden V; Goodfield MJ
    Br J Dermatol; 1996 Aug; 135(2):305-6. PubMed ID: 8881680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxic epidermal necrolysis in a patient with severe aplastic anemia treated with cyclosporin A and G-CSF.
    Robak E; Robak T; Góra-Tybor J; Chojnowski K; Strzelecka B; Waszczykowska E; Sysa-Jedrzejowska A
    J Med; 2001; 32(1-2):31-9. PubMed ID: 11321886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of granulocyte colony-stimulating factor in the treatment of toxic epidermal necrolysis--experience with 3 patients.
    Mahajan R; Kanwar AJ
    Skinmed; 2013; 11(5):269-71. PubMed ID: 24340465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte colony stimulating factor treatment for delayed recovery of ticlopidine-related neutropenia.
    Hung MJ; Wang CH; Cherng WJ
    Int J Clin Pract; 2002; 56(1):70-1. PubMed ID: 11831843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive effects of infection and neutropenia on the induction of granulocytopoietic activity in vivo.
    Bönig HB; Hannen M; Lex C; Wölfel S; Banning U; Nürnberger W; Körholz D; Göbel U
    Cancer; 1999 Jul; 86(2):340-8. PubMed ID: 10421271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial therapeutic effect of plasmapheresis after unsuccessful treatment with corticosteroids in two patients with severe toxic epidermal necrolysis.
    Szczeklik W; Nowak I; Seczynska B; Sega A; Krolikowski W; Musial J
    Ther Apher Dial; 2010 Jun; 14(3):354-7. PubMed ID: 20609191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists.
    Danova M; Rosti G; De Placido S; Bencardino K; Venturini M
    Oncol Rep; 2005 Dec; 14(6):1405-12. PubMed ID: 16273232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxic epidermal necrolysis treated with intravenous immunoglobulin and granulocyte colony-stimulating factor.
    Kalyoncu M; Cimsit G; Cakir M; Okten A
    Indian Pediatr; 2004 Apr; 41(4):392-5. PubMed ID: 15123870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, noncomparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis.
    Al-Mutairi N; Arun J; Osama NE; Amr Z; Mazen AS; Ibtesam el-A; Nazeha el-B
    Int J Dermatol; 2004 Nov; 43(11):847-51. PubMed ID: 15533072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxic epidermal necrolysis/Stevens-Johnson syndrome: current trends in management.
    Dalli RL; Kumar R; Kennedy P; Maitz P; Lee S; Johnson R
    ANZ J Surg; 2007 Aug; 77(8):671-6. PubMed ID: 17635282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological and clinical correlates after chemotherapy and granulocyte colony-stimulating factor administration.
    Higa GM; DeVore RF; Auber ML; Lynch JP; Landreth KS
    Pharmacotherapy; 1998; 18(1):1-8. PubMed ID: 9469674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical utility of granulocyte colony-stimulating factor: early achievements and future promise.
    Morstyn G; Foote M; Perkins D; Vincent M
    Stem Cells; 1994; 12 Suppl 1():213-27; discussion 227-8. PubMed ID: 7535147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of toxic epidermal necrolysis/Stevens-Johnson syndrome overlap with human granulocyte colony stimulating factor: a case report.
    Pallesen KA; Robinson S; Toft P; Andersen KE
    Acta Derm Venereol; 2012 Mar; 92(2):212-3. PubMed ID: 22068367
    [No Abstract]   [Full Text] [Related]  

  • 19. Toxic epidermal necrolysis successfully treated with etanercept.
    Gubinelli E; Canzona F; Tonanzi T; Raskovic D; Didona B
    J Dermatol; 2009 Mar; 36(3):150-3. PubMed ID: 19335689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hematopoietic growth factors in prophylaxis and therapy of infections complications in children with neutropenia].
    Lehrnbecher T
    Klin Padiatr; 2001; 213(4):212-38. PubMed ID: 11528556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.